Funding Details
- Awarder
- Inbox
- Date Award
- January 29, 2025
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Valuation
-
$212,900,000
Company Info
- Traction
- The IPO is expected to raise CHF 75 million, with a potential increase to CHF 80 million through an over-allotment option. The company has received commitments from GSK and the AMR Action Fund.
- Organizations Involved
- GSK, AMR Action Fund
- Founders
- Marc Gitzinger, Dr. Sergio Lociuro
- Company Description
- BioVersys AG is a clinical-stage biopharmaceutical company dedicated to developing novel antibacterial treatments for life-threatening infections caused by multidrug-resistant (MDR) bacteria.
- Market
- Antibacterial treatments for life-threatening infections
- Location
-
Switzerland
- Coinvestors
- Glaxo Group Limited, AMR Action Fund
Links